Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC is an Associate Professor of Medicine within the Division of Cardiology at Johns Hopkins University and also holds a joint appointment in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She is the Director of Women’s Cardiovascular Health Research and the Associate Director of Preventive Cardiology at the Ciccarone Center for the Prevention of Cardiovascular Disease at Johns Hopkins, and also an Associate Faculty of the Welch Center for Prevention, Epidemiology and Clinical research.
Dr. Michos is an internationally-known expert in Women’s Cardiovascular Health and Preventive Cardiology, and has been an invited lecturer on these topics all over the world. Dr. Michos is an established clinician scientist and has authored over 680 manuscripts published in peer-reviewed journals and 11 book chapters. She has an H-index of 89, an I-index of 429, and over 40,000 citations.
Her research focuses in particular (1) Cardio-Obstetrics & maternal health; (2) Cardiovascular disease (CVD) prevention in women; (3) Disparities in enrollment of women & diverse populations in CV clinical trials; (4) Risk prediction for CVD including coronary artery calcium scores, cardiac troponin, markers of inflammation, and other novel biomarkers; (5) lipid management; (6) cardiometabolic & cardiorenal disease and diabetes; (7) vitamin D, calcium, and other supplements and their impact on CVD risk.
Dr. Michos is the Co-Center Director for the IMPACT (Improving Participation of Diverse Populations in Clinical Trials) Center at Johns Hopkins, funded by the American Heart Association (AHA) as part of the Strategic Focused Research Network (SFRN) for studying the Science of Diversity of Clinical Trials. Much of her research has focused on studying diversity in clinical trials; she has also participated in leading clinical trials. For the NIH/NIA-funded STudy to Understand Fall Reduction and Vitamin D in You (STURDY) clinical trial evaluating vitamin D supplements for fall prevention (NCT02166333, PI Lawrence Appel), she chaired the design committee, was the clinical site director of the Comstock field center, and a member of the Steering Committee. For the NIH/NHLBI-funded trial MESA INVITE (INdividualized response to VItamin D TrEatment) trial (NCT02925195), she was the local PI at the Hopkins field center. For the Supplements, Placebo, or Rosuvastatin Study (SPORT) trial (NCT04846231), she served on the Steering Committee.
Dr. Michos is a recognized thought leader in CVD prevention, serving on the ACC Prevention Leadership Council and the Board of Directors for the American Society of Preventive Cardiology (ASPC). She is
the co-Editor in Chief of the American Journal of Preventive Cardiology, the only U.S. journal devoted entirely to preventive cardiology. She previously served as an Associate Editor for Circulation (an AHA journal, with impact factor of 29) and a Guest Editor for the Journal of American College of Cardiology (JACC) (impact factor 24). She is also the Guest Section Editor for the Lipids, Women’s Health, and Cardio-Obstetrics special issues for Current Cardiology Reports, Current Cardiovascular Risk Reports, and Frontiers in Cardiovascular Medicine journals, respectively.
Dr. Michos has participated in multiple national and international society guidelines and position statements. She was a co-author on the 2017 American Diabetes Association (ADA) statement on Hypertension and the 2020 KDIGO Guideline on the Management of Diabetes in Chronic Kidney Disease and the 2022 KDIGO guideline update. Additionally, she was a co-author on the 2019 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on the Primary Prevention of CVD, the AHA’s 2017 Scientific Statement on Meditation, the AHA’s 2021 Statement on the Mind-Heart-Body connection, and the AHA’s 2022 statement on Optimizing Maternal Cardiovascular Health. She was on the writing committee for the AHA 2023 and 2024 Heart Disease and Stroke Statistics Document where she authored/coauthored the Obesity and the Adverse Pregnancy Outcomes Chapters, and will again be a coauthor on the 2025 AHA stats document.
Dr. Michos serves in multiple leadership roles for the AHA including being a prior member of the AHA’s Funding Committee and the AHA’s Research and Publication Committee for the AHA COVID Cardiovascular Registry. She served on the planning committee for the AHA Research Leadership Academy (RLA) for the past 3 years. She is also on a small taskforce for the AHA to help modernize the AHA Scientific Statements as well as another AHA subcommittee on forecasting trends in CVD risk.
In addition to her aforementioned expertise in women’s cardiovascular health and preventive cardiology, Dr. Michos has extensive experience as an investigator in NIH-funded cohort studies. She has been a co-investigator in the Multi-Ethnic Study of Atherosclerosis (MESA) study, the MultiCenter AIDS Cohort Study (MACS)/ Women’s Interagency HIV Study (WIHS) Combined Cohort Study (MACS/WIHS-CSS), the Atherosclerosis Risk in Communities (ARIC) study. In both the ARIC and MACS/WHIHS-CSS studies she serves in the role of CVD event adjudication.
Dr. Michos is well-established mentor, having mentored over 60 individuals in her career. She has been the Training Director for 4 AHA Strategic Focused Research Networks, and is a faculty advisor on 3 different T32 training grants. In recognition of her exemplary mentorship, Dr. Michos was the recipient of 2 mentoring awards in the Department of Medicine and School of Medicine, respectively, at Johns Hopkins University.
As the Director of Women’s Cardiovascular Health Research at Johns Hopkins School of Medicine and the Co-Center Director of the IMPACT (Improving Participation Among Diverse Populations in Cardiovascular Clinical Trials) Center at Johns Hopkins University, funded by the AHA, Dr. Michos brings extensive experience and leadership in women’s cardiovascular health, clinical trial diversity, and mentorship, particularly for early-career women faculty.
